Monthly Archives: November 2015

The Race to Yes: Where Do We Stand Today?

July 2012 Drug company Sarepta announces that after 36 weeks of dosing, DMD participants using eteplirsen outperformed the placebo. The company had demonstrated three months earlier that eteplirsen results in the production of significant levels of dystrophin, the protein boys with Duchenne are missing. December 2012 Sarepta requests a meeting with the FDA to determine… Read more »